Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 204

The DOI matches its Crossref record.

Phase I study of BMS-663513, a fully human anti-CD137 agonist monoclonal antibody, in patients (pts) with advanced cancer (CA)

Sznol, M., Hodi, F. S., Margolin, K., McDermott, D. F., Ernstoff, M. S., Kirkwood, J. M., Wojtaszek, C., Feltquate, D., Logan, T. · 2008 · Journal of Clinical Oncology

Abstract

3007 Background: CD137 is a member of the TNFR family and functions as a costimulatory molecule. In preclinical studies BMS- 663513, a fully human anti-CD137 agonist monoclonal antibody provided costimulation to CD8+ and CD4+ T-cells, leading to enhanced IFNγ production, cytolytic activity, and increased survival. We conducted a first-in-human phase I dose-escalation study of BMS-663513 in pts with CA. Methods: BMS-663513 was administered IV every 3 weeks. In Part 1, the dose was escalated (0.3, 1, 3, 6, 10, and 15 mg/kg) in cohorts of 3–6 pts. In Part 2, pts with melanoma, RCC, and ovarian CA, 30 per CA, were stratified by tumor type and randomized to receive 1, 3, and 10 mg/kg dose levels. Tumor response (modified WHO) was determined after the 4th dose and then every 2 doses. After 4 doses, treatment continued in pts with antitumor activity and without dose-limiting toxicity (DLT). Tumor biopsies were obtained from pts in Part 1 pretreatment and during cycle 2; PBMC, serum, and plasma were also obtained from all pts at select times for exploratory biomarker analysis. Results: 83 pts (54 melanoma, 15 RCC, 13 ovarian and 1 prostate) have been treated. Part 2 melanoma enrollment is complete. In Part 1, single DLTs were reported in the 0.3 mg/kg (Gr 3 neutropenia), and 15 mg/kg (Gr 4 neutropenia) cohorts. Overall, fatigue (All, 26%, Gr 3–4, 3%), reversible Gr 3–4 transaminitis (11%) and Gr 3–4 neutropenia (5%) were the most common agent-related AEs. 3 PRs (18+ mo, 3+ mo, 1.5+ mo, all melanoma) and 4 SD (10 mo, 6 mo, 6 mo, 4+ mo) occurred at all three doses tested in expansion cohorts. Preliminary biomarker analysis demonstrated increased expression of IFN-inducible genes in peripheral blood, serum neopterin levels, and percentage of circulating activated (HLA-DR+, CD69+) CD8 and CD4 T-cells following a single treatment. Increased expression of CD8a and IFNγ were detected in post- treatment biopsies in a subset of pts. Conclusions: BMS-663513 was tolerable across a wide dose range (0.3–15 mg/kg). As a single agent, BMS-663513 demonstrates clinical activity that justifies its further evaluation both as a single agent and in combination with other treatment modalities. Author Disclosure Employment or Leadership Consultant or Advisory Role Stock Ownership Honoraria Research Expert Testimony Other Remuneration Bristol-Myers Squibb Bristol-Myers Squibb Bristol-Myers Squibb

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1200/jco.2008.26.15_suppl.3007

Cites

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cited by

See all 204

Metadata

Authors
Sznol, M., Hodi, F. S., Margolin, K., McDermott, D. F., Ernstoff, M. S., Kirkwood, J. M., Wojtaszek, C., Feltquate, D., & Logan, T.
Venue
Journal of Clinical Oncology
Published
2008-05-20
Volume
26
Issue
15_suppl
Pages
3007-3007
ISSN
  • 0732-183X (ISSN-L)
  • 1527-7755
OpenAlex
W2136364651
Cited by
204
References
0
Type
conference abstract
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Phase I study of BMS-663513, a fully human anti-CD137 agonist monoclonal antibody, in patients (pts) with advanced cancer (CA). https://app.cochat.ai/papers/10.1200/jco.2008.26.15_suppl.3007
The paper
Sznol, M., Hodi, F. S., Margolin, K., McDermott, D. F., Ernstoff, M. S., Kirkwood, J. M., Wojtaszek, C., Feltquate, D., & Logan, T. (2008). Phase I study of BMS-663513, a fully human anti-CD137 agonist monoclonal antibody, in patients (pts) with advanced cancer (CA). Journal of Clinical Oncology. https://doi.org/10.1200/jco.2008.26.15_suppl.3007

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.